CDCA5 PEPTIDES AND VACCINES INCLUDING THE SAME
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 2, 2013
app pub date -
Apr 7, 2011
filing date -
Apr 9, 2010
priority date (Note) -
Abandoned
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Abstract
Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.
First Claim
all claims..Other Claims data not available
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
ONCOTHERAPY SCIENCE INC | 2-1 SAKADO 3-CHOME TAKATSU-KU KAWASAKI-SHI 2130012 |
International Classification(s)
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Nakamura, Yusuke | Tokyo, JP | 416 | 3218 |
# of filed Patents : 416 Total Citations : 3218 | |||
Ohsawa, Ryuji | Kanagawa, JP | 41 | 163 |
# of filed Patents : 41 Total Citations : 163 | |||
Tsunoda, Takuya | Kanagawa, JP | 101 | 492 |
# of filed Patents : 101 Total Citations : 492 | |||
Watanabe, Tomohisa | Kanagawa, JP | 54 | 78 |
# of filed Patents : 54 Total Citations : 78 | |||
Yoshimura, Sachiko | Kanagawa, JP | 65 | 189 |
# of filed Patents : 65 Total Citations : 189 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
- 0 Citation Count
- C07K Class
- 0 % this patent is cited more than
- 12 Age
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events
- No Legal Status data available.

Matter Detail

Renewals Detail
